Lacipil

Lacidipine, the active ingredient in Lacipil, is a dihydropyridine calcium channel blocker presented as a tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension. The medication is indicated for essential hypertension and may be used as part of combination therapy when monotherapy is insufficient.

GNH USA supplies Lacipil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Lacidipine is used to treat hypertension by relaxing vascular smooth muscle and reducing peripheral resistance. - Essential hypertension: lowers systolic and diastolic blood pressure in patients with primary high blood pressure. - Isolated systolic hypertension: reduces elevated systolic pressure, especially in older adults. - Hypertension as adjunct therapy: may be combined with other antihypertensives when single‑drug control is inadequate.

Lacidipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness

Serious or Rare Side Effects: - Severe hypotension - Acute myocardial infarction - Angioedema

When prescribing Lacidipine, clinicians should observe several precautions to ensure safe use. - Blood pressure monitoring: regularly assess to avoid excessive hypotension. - Hepatic impairment: use with caution and consider dose adjustment in patients with liver dysfunction. - Elderly patients: start at low dose and monitor for orthostatic effects. - Concomitant antihypertensives: evaluate for additive blood‑pressure lowering effects. - Hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in the original container, protect from moisture and light.

Lacidipine can interact with other medicines, influencing its plasma concentration or enhancing pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase Lacidipine levels. - Grapefruit juice: can elevate drug exposure and risk of hypotension. - Co‑administration with other potent vasodilators: may cause dangerous drops in blood pressure.

Moderate Interactions (Monitor Closely): - Calcium supplements or antacids: may reduce oral absorption of Lacidipine. - Beta‑blockers: require monitoring of heart rate and blood pressure. - Diuretics: watch for electrolyte disturbances and additive hypotensive effect.